行情

RETA

RETA

Reata制药
NASDAQ

实时行情|Nasdaq Last Sale

224.03
-4.11
-1.80%
已收盘, 19:31 02/19 EST
开盘
228.01
昨收
228.14
最高
228.01
最低
220.35
成交量
31.92万
成交额
--
52周最高
257.97
52周最低
70.00
市值
67.82亿
市盈率(TTM)
-52.1097
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RETA 新闻

  • 巴西央行将定期存款准备金利率从31%下调至25%
  • 新浪财经.11分钟前
  • 三只股票成“派息大户”,投资者稳赚不亏?
  • 新浪财经-自媒体综合.20分钟前
  • 福布斯发布区块链50强:蚂蚁金服、腾讯、百度等上榜
  • TechWeb.44分钟前
  • 英伟达数据中心业务2020财年营收接近30亿美元
  • TechWeb.49分钟前

更多

所属板块

生物技术和医学研究
+1.01%
制药与医学研究
+0.22%

热门股票

名称
价格
涨跌幅

RETA 简况

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
展开

Webull提供Reata Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。